On this page
B9D1
B9 domain containing 1
B9D1 is located on the short (p) arm of chromosome 17, at band 17p11.2. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 17 in the library →Available at Jeen Health
Clinical tests that include this
Overview
B9D1 encodes a 204-amino-acid protein that forms part of the transition zone at the base of primary cilia [PMID:21565611]. This cellular compartment regulates the passage of molecules into and out of the cilium, maintaining the distinct biochemical environment required for proper signalling. The gene is located on chromosome 17p11.2 and follows an autosomal recessive inheritance pattern, meaning pathogenic variants in both copies must be present to cause disease.
Disruption of B9D1 function impairs the assembly and maintenance of primary cilia, structures essential for transmitting developmental signals during embryonic growth [PMID:20410501]. Consequently, biallelic B9D1 variants result in conditions affecting the brain, kidneys, liver, and skeletal system, with clinical presentations ranging from severe congenital malformations to intellectual disability.
What the gene does
The B9D1 protein localises specifically to the transition zone, a cylindrical structure at the base of the primary cilium that acts as a selective gate controlling protein and lipid traffic between the ciliary membrane and the cell body [PMID:21565611]. This gatekeeper function ensures that signalling receptors and downstream effectors accumulate correctly within the cilium, enabling the organelle to detect and respond to extracellular cues.
Primary cilia coordinate multiple developmental pathways including Sonic Hedgehog signalling, which patterns the central nervous system and limbs, and planar cell polarity pathways that orient tissues during morphogenesis [PMID:20410501]. The B9D1 protein interacts with other transition zone components to establish and maintain the diffusion barrier that underpins these functions. Without functional B9D1, cilia lose their selective permeability, signalling pathways become dysregulated, and developmental programmes controlling brain architecture, kidney tubule formation, and liver ductal organisation fail to execute properly.
The protein's role extends beyond embryogenesis; functional cilia remain important in postnatal life for maintaining tissue homeostasis and coordinating cellular responses to mechanical and chemical stimuli.
Video: Genetics 101
Chromosome location
B9D1 resides on the short arm of chromosome 17 at position p11.2, a chromosomal region spanning approximately 20 million base pairs. The gene comprises multiple exons that together encode the 204-amino-acid protein product. This genomic location places B9D1 within a gene-dense region subject to occasional structural rearrangements, though the majority of pathogenic variants in B9D1 arise from point mutations or small insertions and deletions rather than large-scale chromosomal alterations.
Protein structure
The B9D1 protein contains a C2 B9-type domain spanning amino acids 9 to 127, which represents the core functional module responsible for protein-protein interactions within the transition zone complex [PMID:21565611]. This domain adopts a fold that facilitates binding to other ciliary proteins, anchoring B9D1 within the transition zone architecture. The C-terminal region includes a disordered segment from amino acids 182 to 204, a flexible region that may participate in regulatory interactions or provide structural adaptability during ciliary assembly. The B9-type domain family is evolutionarily conserved across ciliated organisms, reflecting the fundamental importance of transition zone organisation for ciliary function.
Key variants
Pathogenic variants in B9D1 typically include nonsense mutations, frameshift insertions or deletions, and splice-site alterations that abolish or severely reduce protein expression [PMID:20410501]. Missense variants affecting the C2 B9-type domain can also disrupt protein function by interfering with critical binding interactions. The majority of disease-causing variants result in loss of functional protein, consistent with the autosomal recessive inheritance pattern observed in affected families. Carrier status for a single pathogenic B9D1 variant does not cause clinical features, but individuals with variants in both gene copies develop ciliopathy phenotypes of variable severity.
Sample of pathogenic variants
9 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.341+2T>C | - | Pathogenic/Likely pathogenic | ★★☆☆ | Joubert syndrome 27 |
c.341G>A | p.Arg114Gln | Pathogenic/Likely pathogenic | ★★☆☆ | Joubert syndrome 27 |
c.466C>T | p.Arg156Trp | Pathogenic/Likely pathogenic | ★★☆☆ | Joubert syndrome 27 |
c.285_341+154del | - | Pathogenic | ★☆☆☆ | Meckel-Gruber syndrome |
c.307dup | p.Tyr103fs | Pathogenic | ★☆☆☆ | Inborn genetic diseases |
c.391C>T | p.Gln131Ter | Pathogenic | ★☆☆☆ | Joubert syndrome |
c.403del | p.Ser135fs | Pathogenic | ★☆☆☆ | Meckel-Gruber syndrome |
c.460G>T | p.Glu154Ter | Pathogenic | ★☆☆☆ | Joubert syndrome |
c.517GTG[1] | p.Val174del | Pathogenic | - | Joubert syndrome 27 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in B9D1 cause ciliopathy syndromes characterised by brain malformations, particularly affecting the cerebellum and brainstem [PMID:20410501]. The clinical spectrum includes Joubert syndrome, defined by a distinctive 'molar tooth sign' on brain imaging alongside developmental delay and abnormal breathing patterns in infancy, and Meckel syndrome, a more severe presentation featuring occipital encephalocele, cystic kidney dysplasia, and liver fibrosis, often leading to pregnancy loss or early neonatal death. Some individuals present with overlapping features that do not fit neatly into a single syndrome category, reflecting the variable effects of different B9D1 variants on cilia function across organ systems.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic B9D1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
B9D1 appears on multiple NHS Genomic Medicine Service gene panels with green ratings, indicating strong evidence for its role in genetic disease. The gene is included in the DDG2P panel for developmental disorders, the Fetal Anomalies panel (version R21), and the Intellectual Disability panel (version R29). These classifications support the use of B9D1 testing in UK clinical practice for individuals presenting with features suggestive of ciliopathy syndromes or unexplained neurodevelopmental conditions, and for carrier screening in families with a known B9D1 variant.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
No specific lifestyle modifications have been shown to prevent or modify the course of conditions caused by B9D1 variants, as these result from developmental disruptions during embryogenesis.
Supplement considerations
No dietary supplements have been shown to prevent or treat ciliopathy conditions caused by B9D1 variants. Individuals considering any supplementation should discuss this with their healthcare provider.
Frequently asked questions
What does it mean to be a carrier of a B9D1 variant?
Carriers have one pathogenic B9D1 variant and one working gene copy, which produces sufficient protein for normal cilia function. Carriers do not develop ciliopathy symptoms but can pass the variant to their children.
If both parents are B9D1 carriers, what is the chance their child will be affected?
Each child has a 25% chance of inheriting both pathogenic variants and being affected, a 50% chance of being a carrier like the parents, and a 25% chance of inheriting two working copies. Genetic counselling and reproductive options are available for carrier couples.
Are there treatments for conditions caused by B9D1 variants?
Management focuses on supportive care tailored to each individual's symptoms, which may include physiotherapy for motor delays, educational support for learning difficulties, and monitoring for kidney or liver complications. No treatments currently restore normal B9D1 protein function.